Heplisav-B Review Still On Track Even After Cancelled Advisory Cmte., Dynavax Says

Related Content

Heplisav Vaccine Postmarketing Study Might Overcome FDA Safety Worries At Panel

Valbenazine FDA Panel Cancellation Is A Good Sign, Neurocrine Says

US FDA Review Management Challenged After Spate Of Complete Response Letters

Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin

From Solanezumab To Solithromycin: What To Watch For In Q4

Stockwatch: Dynavax, CoLucid Investors Should Beware The Standard Of Care

Dynavax Hep B Vaccine Gets Second Panel Review; Scrutiny On Safety, Superiority

Will Dynavax’ HBV Vaccine Resubmission Make The Safety Grade?

FDA Panel Considers Dynavax’s Heplisav Safety Database Insufficient

Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults